PROLIFIC

Three Lakes 12-20 is a member of the PROLIFIC Consortium which was formed to develop well-qualified assays to measure selected blood-based protein biomarkers linked to IPF.   The consortium members include leading pharmaceutical companies and foundations. 

www.pulmonaryfibrosis.org

PROLIFIC | Pulmonary Fibrosis Foundation

PROLIFIC aims to guide and streamline the development of targeted treatment strategies for patients with pulmonary fibrosis.

Development of the assays was presented at the 2024 American Thoracic Society (ATS) meeting:

https://www.atsjournals.org/doi/epdf/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A3685?role=ta

Related Publication:

“Circulating biomarker analyses in a longitudinal cohort of patients with IPF” published in Am. J. Physiol. Lung Cell. Mol. Physiol. Reference